{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:15:11Z","timestamp":1783480511303,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13429-w","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:26:31Z","timestamp":1778678791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined injectable regimens in treatment-experienced HIV\/AIDS patients at a southern academic medical center: a case series"],"prefix":"10.1186","volume":"26","author":[{"given":"Helen Jensie","family":"Burton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Rivere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Lueking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"issue":"3","key":"13429_CR1","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s10461-020-03055-1","volume":"25","author":"P de Los Rios","year":"2021","unstructured":"de Los Rios P, Okoli C, Castellanos E, Allan B, Young B, Brough G, et al. Physical, Emotional, and Psychosocial Challenges Associated with Daily Dosing of HIV Medications and Their Impact on Indicators of Quality of Life: Findings from the Positive Perspectives Study. AIDS Behav. 2021;25(3):961\u201372.","journal-title":"AIDS Behav"},{"issue":"4","key":"13429_CR2","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/QAI.0000000000002466","volume":"85","author":"G Rizzardini","year":"2020","unstructured":"Rizzardini G, Overton ET, Orkin C, Swindells S, Arasteh K, Gorgolas Hernandez-Mora M, et al. Long-Acting Injectable Cabotegravir\u2009+\u2009Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials. J Acquir Immune Defic Syndr. 2020;85(4):498\u2013506.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"13429_CR3","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","volume":"10","author":"MN Ramgopal","year":"2023","unstructured":"Ramgopal MN, Castagna A, Cazanave C, Diaz-Brito V, Dretler R, Oka S, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):e566\u201377.","journal-title":"Lancet HIV"},{"issue":"3","key":"13429_CR4","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1093\/cid\/ciac631","volume":"76","author":"KA Christopoulos","year":"2023","unstructured":"Christopoulos KA, Grochowski J, Mayorga-Munoz F, Hickey MD, Imbert E, Szumowski JD, et al. First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable Human Immunodeficiency Virus (HIV) Viremia in an Urban HIV Clinic. Clin Infect Dis. 2023;76(3):e645\u201351.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"13429_CR5","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/phar.2922","volume":"44","author":"EM Sherman","year":"2024","unstructured":"Sherman EM, Agwu AL, Ambrosioni J, Behrens GMN, Chu C, Collins LF, et al. Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2024;44(7):494\u2013538.","journal-title":"Pharmacotherapy"},{"issue":"8","key":"13429_CR6","doi-asserted-by":"publisher","first-page":"ofaf446","DOI":"10.1093\/ofid\/ofaf446","volume":"12","author":"RM Kagan","year":"2025","unstructured":"Kagan RM, Baxter JD, Kim T, Marlowe EM. HIV-1 Drug Resistance Trends in the Era of Modern Antiretrovirals: 2018\u20132024. Open Forum Infect Dis. 2025;12(8):ofaf446.","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"13429_CR7","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1016\/S2352-3018(23)00113-3","volume":"10","author":"O Ogbuagu","year":"2023","unstructured":"Ogbuagu O, Segal-Maurer S, Ratanasuwan W, Avihingsanon A, Brinson C, Workowski K, et al. Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2\/3 trial. Lancet HIV. 2023;10(8):e497\u2013505.","journal-title":"Lancet HIV"},{"issue":"19","key":"13429_CR8","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","volume":"386","author":"S Segal-Maurer","year":"2022","unstructured":"Segal-Maurer S, DeJesus E, Stellbrink HJ, Castagna A, Richmond GJ, Sinclair GI, et al. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2022;386(19):1793\u2013803.","journal-title":"N Engl J Med"},{"issue":"4","key":"13429_CR9","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/QAI.0000000000002591","volume":"86","author":"JC Gathe","year":"2021","unstructured":"Gathe JC, Hardwicke RL, Garcia F, Weinheimer S, Lewis ST, Cash RB. Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study. J Acquir Immune Defic Syndr. 2021;86(4):482\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"13429_CR10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1128\/AAC.00942-08","volume":"53","author":"JM Jacobson","year":"2009","unstructured":"Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, Larson JA, Weinheimer SP, et al. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother. 2009;53(2):450\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"13429_CR11","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2352-3018(22)00291-0","volume":"10","author":"SK Gupta","year":"2023","unstructured":"Gupta SK, Berhe M, Crofoot G, Benson P, Ramgopal M, Sims J, et al. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. Lancet HIV. 2023;10(1):e15\u201323.","journal-title":"Lancet HIV"},{"issue":"22","key":"13429_CR12","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1056\/NEJMoa035026","volume":"348","author":"JP Lalezari","year":"2003","unstructured":"Lalezari JP, Henry K, O\u2019Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348(22):2175\u201385.","journal-title":"N Engl J Med"},{"issue":"7","key":"13429_CR13","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa1711460","volume":"379","author":"B Emu","year":"2018","unstructured":"Emu B, Fessel J, Schrader S, Kumar P, Richmond G, Win S, et al. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. N Engl J Med. 2018;379(7):645\u201354.","journal-title":"N Engl J Med"},{"issue":"4","key":"13429_CR14","doi-asserted-by":"publisher","first-page":"ofae125","DOI":"10.1093\/ofid\/ofae125","volume":"11","author":"M Gandhi","year":"2024","unstructured":"Gandhi M, Hill L, Grochowski J, Nelson A, Koss CA, Mayorga-Munoz F, et al. Case Series of People With HIV on the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial. Open Forum Infect Dis. 2024;11(4):ofae125.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"13429_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/09564624241288293","volume":"36","author":"KL O\u2019Neil","year":"2025","unstructured":"O\u2019Neil KL, Ching PR, Higginson RT, Pecora Fulco P. Case series of two persons living with HIV with detectable viral loads initiated then suppressed on cabotegravir\/rilpivirine with lenacapavir. Int J STD AIDS. 2025;36(2):155\u20137.","journal-title":"Int J STD AIDS"},{"issue":"5","key":"13429_CR16","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1016\/S2352-3018(23)00051-6","volume":"10","author":"JB Nachega","year":"2023","unstructured":"Nachega JB, Scarsi KK, Gandhi M, Scott RK, Mofenson LM, Archary M, et al. Long-acting antiretrovirals and HIV treatment adherence. Lancet HIV. 2023;10(5):e332\u201342.","journal-title":"Lancet HIV"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13429-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13429-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13429-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:28:58Z","timestamp":1783477738000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13429-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13429"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13429-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was deemed IRB exempt per Medical University of South Carolina Institutional Review Board policy, as it reports an effort to improve quality of care within this clinic. The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and relevant institutional policies. No identifiable patient information was included, and individual consent was not required. Clinical trial number: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable as no identifiable individual information was included.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1266"}}